7th Annual Discovery Luncheon
Where: Delta Hotel by Marriott Grand Okanagan Resort
When: 11:30am (registration) and 12:00pm - 1:15pm (event)
Tickets: $75/each or $600 for a table of 8
We are looking forward to the 7th Annual Discovery Luncheon in Kelowna in November, 2017 where enhancements to patient care and research, right here in our community, will continue to be supported. This year's fundraising focus is the purchase and installation of a new PET/CT scanner at the BC Cancer Agency Sindi Ahluwalia Hawkins Centre for the Southern Interior.
PET/CT is vital in helping doctors diagnose cancer and create treatment plans for patients.There are currently only two publicly funded PET/CT scanners in B.C., both located at the BC Cancer Vancouver Centre.
Currently, more than 800 patients from the Southern Interior have to travel to Vancouver each year for a PET/CT scan they're counting on to save their lives. Many more are too unwell or don't have the support network to make the trip. With your help, PET/CT technology can provide more people with the most effective cancer care possible, without having to leave the region.
Past Discovery Luncheons have supported BC Cancer Agency researchers in making huge strides:
- Expanded brachytherapy treatment program for women with gynaecological cancers.
- HDR brachytherapy “boost” (implanted radiation in addition to standard external beam radiation) has become standard treatment for patients with high-tier intermediate and high-risk prostate cancer. It is now possible to perform three HDR procedures in a standard operating day, an achievement seen as impossible just a short time ago;
- A pilot program is underway to determine the proportion of patients eligible for breast seed brachytherapy, improve the technique, adapt it for different breast sizes and tumour locations and incorporate new 3D ultrasound technology;
- The PREDICT (Personal REsponse Determinants in Cancer Therapy) is now more than half-way to its goal of 20,000 participants, which will enable large-scale cancer and genomic research across many tumour types;
- More than 20 clinical trials are currently underway including breast, prostate, lung, bladder and lymphoid cancer;
- The Personalized Onco-Genomics (POG) Program is currently expanding to 2,000 patients. This added scope will provide researchers with valuable outcome data that will enable genomics to be integrated into standard cancer care.
PARTNERS IN DISCOVERY SPONSORS